MyFinsight
Home
Blog
About
Contact
Download
Download image
Loss attributable to
common stockholders
-$12,518,480
Net loss
-$12,518,480
Interest income and
other, net
$95,472
Loss from operations
-$12,613,952
Total operating
expenses
$12,613,952
Acquired in-process
research and development
$8,517,966
General and
administrative
$3,727,816
Research and development
$368,170
Back
Back
Income Statement
source: myfinsight.com
Decoy Therapeutics Inc. (DCOY)
Decoy Therapeutics Inc. (DCOY)